1. Introduction {#sec1}
===============

Primary liver cancer is the sixth most common cancer and the third most common cause of cancer-related deaths. 70%\~90% primary liver cancers occurring worldwide are hepatocellular carcinoma (HCC), which is the fastest growing cause of cancer-related death globally \[[@B1], [@B2]\]. Recent epidemiology data revealed that liver cancer might account for more cancer-related deaths worldwide \[[@B3]\]. HCC has a 5-year survival rate of only 14% approximately \[[@B4]\]. Most HCCs are diagnosed at an intermediate to advanced stage, at which point surgical treatment and/or chemical embolism are no longer feasible \[[@B5]\]. Therefore, to improve outcome of HCC patients, an alternative or novel approach is required.

Previous report showed a large prevalence of a diversity of traditional Chinese medicine (TCM) clinical application for cancer patients \[[@B6]\]. Sufficient evidence has demonstrated that natural compounds with various types of medicinal ingredients can substantially inhibit tumor formation \[[@B7]\]. Many clinical articles have reported that TCM or TCM plus chemotherapy can significantly alleviate symptoms, stabilize tumor size, reinforce the constitution, enhance therapy tolerance and immunological function, obviously reduce the incidence rate of adverse events, and prolong patients\' survival duration for unresectable HCC \[[@B8]--[@B11]\].

Unfortunately, reporting of RCTs on treatment of HCC with TCM is still in low quality, not meeting the CONSORT and TREND statement. High quality of evidence based on the existing clinical information is still unavailable \[[@B6], [@B12]\]. A recent meta-analysis also announced that many RCTs of TCM therapy in HCC are not, in fact, randomized \[[@B13]\]. Thus, only RCTs reported randomized methods were included in our current meta-analysis. The purpose of this study is to systematically review and meta-analyze data from RCTs for evidence on the efficacy and safety of add-on therapy with TCM in the treatment of HCC.

2. Materials and Methods {#sec2}
========================

2.1. Search Strategy and Study Selection {#sec2.1}
----------------------------------------

We searched PubMed, Chinese National Knowledge Infrastructure (CNKI) Database, Wanfang Database, Chinese Biomedical (CBM) Database, Chinese Science and Technology Periodical Database (VIP), Allied and Complementary Medicine Database (AMED), Ovid, Embase, Web of Science, and Cochrane Library databases until June 1, 2016. The following medical subject headings were used: "hepatocellular carcinoma;" "primary liver cancer;" "Traditional Chinese Medicine;" "alternative medicine;" "complementary medicine;" "Chinese herbal medicine;" "herb/herbal;" and "decotion/formulation." Electronic searches were supplemented with manual searches of reference lists used in all of the retrieved review articles, primary studies, and abstracts from meetings to identify other studies not found in the electronic searches. Literature was searched by two authors (Z Yang and X Liao) independently.

Two authors independently selected trials and discussed with each other when inconsistencies were found. Articles that satisfy the following criteria were included: (1) for study types, RCTs with randomized method; (2) for participants, HCCs; (3) for interventions, TCMs compared with placebo or no treatment; in addition, any cointervention had to be the same in both groups except for the TCM formulation; (4) for outcome, overall survival and/or solid tumors responses; and (5) available full texts. If the duration and sources of study population recruitment overlapped by more than 30% in two or more papers by the same authors, we only included the most recent study or the study with the larger number of HCC patients. Studies were excluded if they meet the following criteria: (1) studies "so-called" randomized without randomized methods; (2) studies without control subjects or control participants receiving TCM treatment including herbal medicine and acupuncture; (3) studies reporting only laboratory values and/or symptom improvement rather than survival outcomes and clinical responses.

2.2. Data Extraction and Methodological Quality Assessment {#sec2.2}
----------------------------------------------------------

Two researchers independently read the full texts and extracted the following contents: publication data; study design; sample size; patient characteristics; treatment protocol; and outcome measures. The methodological qualities of the included RCTs were assessed according to Cochrane Collaboration\'s Tool described in Handbook version 5.1.0 \[[@B14]\]. Two authors (Z Yang and X Liao) independently assessed quality, and inconsistency was discussed with other reviewer-authors (Y Yu and X Chen) who acted as arbiters.

2.3. Definitions {#sec2.3}
----------------

All the diagnosis should be according to guidelines. The primary outcome overall survival was defined as the time from HCC diagnosis until the death due to any cause. Solid tumor response is categorized as complete response (CR), partial response (PR), stable disease (SD), progressive disease (PD), and CR + PR as a proportion for total response rate (tRR) according to the World Health Organization (WHO) criteria \[[@B15]\] or the Response Evaluation Criteria In Solid Tumors (RECIST) guidelines \[[@B16], [@B17]\]. Karnofsky performance status (KPS) \[[@B18]\] and adverse events were also measured in our study.

2.4. Statistical Methods {#sec2.4}
------------------------

The effect measures of interest were risk ratios (RRs) and the corresponding 95% confidence intervals (CIs). Heterogeneity across studies was informally assessed by visually inspecting forest plots and formally estimated by Cochran\'s *Q* test in which chi-square distribution is used to make inferences regarding the null hypothesis of homogeneity (considered significant at *P* \< 0.10). A rough guide to our interpretation of *I*^2^ was listed as follows:0% to 40% shows that heterogeneity may not be important.30% to 60% corresponds to moderate heterogeneity.50% to 90% exhibits substantial heterogeneity.75% to 100% indicates considerable heterogeneity \[[@B14], [@B19]\].If the eligibility of some studies in the meta-analysis was uncertain because of missing information, a sensitivity analysis was performed by conducting the meta-analysis twice: in the first meta-analysis, all of the studies were included; in the second meta-analysis, only those that were definitely eligible were included. A fixed-effects model was used initially for our meta-analyses; a random-effects model was then used in the presence of heterogeneity. Description analysis was performed when quantitative data could not be pooled. Review Manager version 5.1 software was used for data analysis.

3. Results {#sec3}
==========

3.1. Study and Patient Characteristics {#sec3.1}
--------------------------------------

Totally, 8990 abstracts were reviewed; among these articles, 393 were retrieved that are closely related to the current subject. The study selection process was summarized in [Figure 1](#fig1){ref-type="fig"}. Finally, 20 RCTs \[[@B20]--[@B39]\] were included in this meta-analysis. The baseline characteristics of included studies are described in [Table 1](#tab1){ref-type="table"}.

3.2. Methodological Quality Assessment {#sec3.2}
--------------------------------------

The methods of randomization were described adequately in all studies \[[@B20]--[@B39]\], which were considered as random number table \[[@B20], [@B21], [@B23], [@B24], [@B27], [@B28], [@B30]--[@B32], [@B34]\], sealed envelopes \[[@B22], [@B26], [@B37]--[@B39]\], randomized block \[[@B25], [@B35]\], draw method \[[@B29], [@B36]\], and randomization according to hospitalized date \[[@B33]\]. We hence considered low risks in terms of selection bias. Except for study reported by Tian et al. \[[@B35]\], blind-methods of other studies were not available, which were considered high risk in terms of performance bias. Detection bias was unclear in all studies with no presenting of blinding of outcome assessment. Less than 15% of participants were lost to follow-up in the three studies \[[@B20], [@B21], [@B25], [@B35]--[@B37], [@B39]\]; these parameters were considered low risk in terms of incomplete outcome data. Selective reporting was found in three studies \[[@B21], [@B25], [@B35]\] because these researches failed to present the clinical data of participants in ITT analysis. Other potential biases were unclear in these trials ([Figure 2](#fig2){ref-type="fig"}).

3.3. Overall Survival {#sec3.3}
---------------------

No heterogeneity was found among the included studies \[[@B21], [@B31], [@B35]\], which reported three-month survival in the two groups. No significance of three-month survival was found in HCC patients between TCM group and control group (RR = 1.03, 95% CI = 0.93--1.15, *P* = 0.58, [Figure 3(3.1)](#fig3){ref-type="fig"}). Heterogeneity was significant when we compared six-month survival and one-year survival (*P* \< 0.00001, *I*^2^ = 80% and *P* \< 0.00001, *I*^2^ = 84%, resp.). As shown in [Figure 3](#fig3){ref-type="fig"}, TCM therapy could significantly prolong six-month survival and one-year survival of HCC patients compared to control (RR = 1.30, 95% CI = 1.06--1.59, and *P* = 0.01 and RR = 1.38, 95% CI = 1.14--1.67, and *P* = 0.0008, resp., [Figure 3(3.2 and 3.3)](#fig3){ref-type="fig"}).

No heterogeneity was found between studies comparing two-year survival and three-year survival between the two groups (*P* = 0.18, *I*^2^ = 30% and *P* = 0.13, *I*^2^ = 40%, resp.). Meta-analysis of RCTs \[[@B22], [@B23], [@B25], [@B26], [@B28]--[@B30], [@B32], [@B33]\] using a random-effects model showed that the two-year survival rate of HCC patients in TCM group was significantly higher than that in control group \[280/614 (45.6%) versus 176/535 (32.9%), RR = 1.44, 95% CI = 1.20--1.72, and *P* \< 0.0001, [Figure 3(3.4)](#fig3){ref-type="fig"}\]. Similarly, the three-year survival rate of HCC patients receiving TCM therapy was significantly higher than that in control group \[194/541 (35.9%) versus 140/494 (28.3%), RR = 1.31, 95% CI = 1.05--1.63, and *P* = 0.02, [Figure 3(3.5)](#fig3){ref-type="fig"}\].

3.4. CR, PR, SD, PD, and tRR {#sec3.4}
----------------------------

As shown in [Table 2](#tab2){ref-type="table"}, no heterogeneity was among comparisons of CR, PR, SD, PD, and tRR. Thus, a fixed-effects model was used. The CR rate of HCC patients in TCM group was higher than that in control group, but no statistical difference was found (RR = 1.47, 95% CI = 0.96--2.24, and *P* = 0.07, Figure S1; see Supplementary Material available online at <https://doi.org/10.1155/2017/3428253>). However, meta-analysis of RCTs \[[@B20], [@B22]--[@B25], [@B27], [@B29], [@B30], [@B32], [@B34]--[@B36], [@B38]\] demonstrated that HCC patients receiving TCM therapy achieved significantly higher PR rate and tRR than those in control group (34.4% versus 26.3%, RR = 1.30, 95% CI = 1.10--1.53, and *P* = 0.002 and 41.6% versus 31.0%, RR = 1.30, 95% CI = 1.16--1.53, and *P* \< 0.0001, resp., Figure S2 and Figure S5). In contrast, HCC patients in TCM group suffered from lower PD rate significantly than those in control group (16.6% versus 26.5%, RR = 0.64, 95% CI = 0.52--0.80, and *P* \< 0.0001, Figure S4). No statistical significance was found when we compared SD rate of HCC patients between TCM group and control group (42.6% versus 43.7%, RR = 0.95, 95% CI = 0.84--1.08, and *P* = 0.47, Figure S3).

3.5. Quality of Life (QOL) {#sec3.5}
--------------------------

In this meta-analysis, KPS scores increasing more than 10 after treatment compared to that before treatment was considered improvement in QOL. 11 RCTs \[[@B20]--[@B22], [@B24], [@B26], [@B27], [@B31], [@B34]--[@B37]\] reported QOL assessment according to KPS scores, with no significance of heterogeneity which existed (*P* = 0.70, *I*^2^ = 0%). As shown in [Figure 4](#fig4){ref-type="fig"}, the QOL improvement rate of HCC patients in TCM group was significantly higher than that in control group \[186/520 (35.8) versus 95/510 (18.6), RR = 2.78, 95% CI = 2.06--3.77, and *P* \< 0.00001\].

3.6. Adverse Events {#sec3.6}
-------------------

Nine RCTs \[[@B21], [@B24], [@B29], [@B30], [@B32], [@B34]--[@B36], [@B38]\] reported the adverse events incidence of HCC patients. The most frequent adverse events were leukopenia, thrombocytopenia, anemia/erythropenia, nausea, vomiting, fever, liver injury, and gastrointestinal discomfort. Meta-analysis indicated that HCC patients in control group had significantly higher risk of suffering from leukopenia, thrombocytopenia, anemia/erythropenia, liver injury, and gastrointestinal discomfort than those receiving TCM therapy (55.9% versus 25.1%, 50.0% versus 19.5%, 28.4% versus 16.8%, 44.4% versus 18.4%, and 32.4% versus 17.8%, respectively, all *P* \< 0.05, [Figure 5](#fig5){ref-type="fig"}). No statistical significance of nausea/vomiting and fever was found between the two groups (*P* = 0.24 and *P* = 0.11, resp., [Figure 5](#fig5){ref-type="fig"}).

4. Discussion {#sec4}
=============

Most newly diagnosed HCC cases are at an intermediate advanced stage, and the therapeutic options are limited to palliative approaches using TACE or chemotherapeutic agents \[[@B5], [@B40]\]. Even worse, many patients poorly respond to TACE or suffer from poor outcomes and side effects with conventional systemic cytotoxic chemotherapy \[[@B40]\], leading to disappointing results of systemic chemotherapies and a poor prognosis. Therefore, novel therapeutic strategies are essential to improve the clinical management of patients with HCC.

With a long history of clinical use, essential components of TCM have gradually become a common used treatment for cancer in China \[[@B41]\]. In particular, TCM has been used to treat HCC extensively and it can be used throughout the whole course of HCC \[[@B42]\]. In the past decades, many compounds derived from Chinese herbals of both preclinical and clinical researches have shown promising potentials in novel anti-HCC natural product development \[[@B43]\]. Previous studies indicated that the effect of TCM has targeted the stimulation of the host immune response for cytotoxic activity against liver cancer by inhibiting proliferation and promoting apoptosis of tumor cells \[[@B7], [@B44]\], thereby improving survival and alleviating palliative approaches-related side effects in HCC patients \[[@B45]--[@B47]\].

This meta-analysis summarized evidence on the effects of TCM therapy for HCC patients, on top of conventional treatment. For survival, it is observed that the additional use of TCM significantly improved six-month, one-year, two-year, and three-year survival rates in HCC cases. Additionally, TCM combination therapy could increase PR rate and tRR and reduce PD rate in this population. Given above, results from our study demonstrated add-on benefits of TCM in improving outcomes of HCC patients. As the molecular pathogenesis of HCC is highly associated with multigene, multifactor, and multistep processes and is quite complicated, add-on TCM therapy combined with other therapeutic options has a promising potential for its multilevel, multitarget, and coordinated intervention effects against HCC \[[@B43]\]. Many active compounds from TCM have shown their noticeable potentials in inhibiting the promotion, proliferation, angiogenesis, and metastasis of HCC \[[@B43], [@B44]\], which may contribute to good tumor response and survival in clinical practice. Although the mechanisms of TCM components in anti-HCC were well reviewed before \[[@B43]\], further in-depth mechanistic studies and well-designed clinical trials are warranted.

Previous work has suggested that QOL is an important predictor of survival for cancer patients \[[@B48]\]. Although more sophisticated approaches of QOL measurement were developed, the KPS scores are still widely recognized as a tool for the assessment of the functional status of cancer patients and highly reliable \[[@B49]\]. Based on the evidence we identified, TCM combination therapy may be considered as an alternative option to improve QOL in HCC patients. Previously, KPS as a predictor of survival has been demonstrated in patients with different kind of cancers \[[@B48], [@B49]\], and few studies focused on the relationship between KPS scores and HCC survival. Whether KPS has a role in predicting HCC outcomes should be focused on in future studies.

Evidence of this meta-analysis also showed that the combination of TCM and chemotherapy significantly reduced adverse events including leukopenia, thrombocytopenia, anemia or erythropenia, liver injury, and gastrointestinal discomfort in HCC patients. However, because of the toxic effects of chemotherapy and anticancer drugs on normal cells and tissues, anticancer drugs and approaches cause many side effects and adverse events with various symptoms, including hematocytopenia, gastrointestinal discomfort (nausea, vomiting, anorexia, and diarrhea), and liver injury. These side effects often influence patients\' QOL and sometimes make the chemotherapy discontinued \[[@B50], [@B51]\]. Consistent with our results, growing evidences suggest that TCM appears to have beneficial effects for prevention and improvement of several chemotherapy-induced side effects \[[@B52], [@B53]\], leading to better outcomes in this population.

This meta-analysis had the following limitations. First, majority of the included studies had small samples, with mid- to low-quality designs. Second, all included studies were conducted in China. According to our experience, only positive results are published in Chinese medical journals. We cautiously drew the conclusion that publication bias might have been present in this meta-analysis. Third, most included studies failed to address blinding assessment, which may influence the objectivity of HCC outcomes. High-quality, well-designed, large sample trials focused on the efficacy and safety of TCM therapy for HCC should be performed in the future.

In conclusion, add-on therapy with TCM could improve overall survival, increase clinical tumor responses, and reduce adverse events in hepatocellular carcinoma. Previous surveys indicated that the trend of TCM use in patients with cancer is on the rise. Surveys have also found that many cancer patients were more inclined to use TCM therapies in combination with conventional therapy rather than in lieu of conventional therapy \[[@B54]\]. Thus, investigating the combined use of TCM and conventional therapy in the oncology setting is urgently essential for practitioners. Evidence-based approaches in the clinic have to be supplemented by experimental studies to unravel cellular and molecular modes of action of TCM treatments \[[@B45]\].
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Figure S1: Complete response (CR) rate comparison between TCM group and control group.

Figure S2: Partial response (PR) rate comparison between TCM group and control group.

Figure S3: Stable disease (SD) rate comparison between TCM group and control group.

Figure S4: Progressive disease (PD) rate comparison between TCM group and control group.

Figure S5: Total response rate (tRR) comparison between TCM group and control group.
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###### 

Characteristics of studies included in the meta-analysis.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                           Number of cases   Control regimen   Chemo\                            TCM intervention   TCM duration (days)                                                         HCC\        Child-Pugh\         KPS\      Randomized method   
                                                                      times                                                                                                                            staging     score               score                         
  ------------------------------- ----------------- ----------------- --------------------------------- ------------------ --------------------------------------------------------------------------- ----------- ------------------- --------- ------------------- --------------------------------
  Huang et al. 2001 \[[@B20]\]    32                30                Palliatively supporting therapy   None               Jianpi Xiaoji oral liquid                                                   30          III, IV             A, B, C   ≥60                 Random number table

  Huang et al. 2009 \[[@B21]\]    40                37                TACE                              1\~2               Ganji decoction                                                             28\~42      II, III             A, B      ≥60                 Random number table

  Li et al. 2008 \[[@B22]\]       50                46                TACE                              2\~7               Chinese toad bufotoxin injection                                            28\~112     *Okuda*I, II, III   A, B      ≥60                 Sealed envelopes

  Li et al. 2013 \[[@B23]\]       31                22                TACE                              3                  Hydroxycamptothecin and Chinese herbal compound                             84          II, III             NA        NA                  Random number table

  Li et al. 2016 \[[@B24]\]       26                26                TACE                              NA                 Aidi injection                                                              30          III, IV             NA        30\~60              Random number table

  Lin et al. 2005 \[[@B25]\]      52                33                TACE                              2                  Hydroxycamptothecin and Shentao Ruangan pill                                56          II, III             A, B      ≥60                 Randomized block

  Ling et al. 2001 \[[@B26]\]     162               151               TACE/PEI                          NA                 Sisheng decoction/Chinese toad bufotoxin injection/norcantharidin tablets   Irregular   II, III             NA        NA                  Sealed envelopes

  Liu 2011 \[[@B27]\]             32                30                Palliatively supporting therapy   None               Chinese herbal compound                                                     21          III, IV             A, B, C   ≥60                 Random number table

  Liu and Lü 2016 \[[@B28]\]      53                53                TACE + PMCT                       3                  Chinese herbal compound                                                     90\~135     NA                  A, B      NA                  Random number table

  Lu 2008 \[[@B29]\]              69                69                TACE                              NA                 Aidi injection                                                              20          NA                  NA        60\~90              Draw method

  Lü et al. 2014 \[[@B30]\]       63                63                TACE                              NA                 Shenyi capsules                                                             60          NA                  NA        60\~90              Random number table

  Min and Zhou 2011 \[[@B31]\]    23                22                Palliatively supporting therapy   None               Chinese herbal compound                                                     84          II, III             A, B      72 ± 8              Random number table

  Ren and Cheng 2004 \[[@B32]\]   104               68                TACE                              NA                 Chinese herbal compound                                                     ≥90         II, III             NA        NA                  Random number table

  Shao et al. 2001 \[[@B33]\]     30                30                TACE                              2\~10              Chinese herbal compound                                                     180\~300    II, III             NA        NA                  According to hospitalized date

  Shi and Tang 2013 \[[@B34]\]    42                56                TACE                              NA                 Kang\'ai injection and Carapacis Trionycis Bolus                            56          NA                  A, B      ≥60                 Random number table

  Tian et al. 2008 \[[@B35]\]     49                48                TACE                              NA                 Chinese herbal compound                                                     28          II, III             A, B      ≥60                 Randomized block, single blind

  Xie et al. 2014 \[[@B36]\]      34                34                TACE                              NA                 Chinese herbal compound                                                     40          NA                  A, B      ≥60                 Draw method

  Yang et al. 2011 \[[@B37]\]     30                30                TACE                              NA                 Aidi injection                                                              30          NA                  A, B, C   ≥70                 Sealed envelopes

  Yi et al. 2008 \[[@B38]\]       28                23                TACE                              3                  Kang\'ai injection                                                          45          II, III             NA        ≥60                 Sealed envelopes

  Zhong et al. 2014 \[[@B39]\]    60                60                Hepatectomy                       None               Chinese herbal compound                                                     365         I\~IIIa             A, B      NA                  Sealed envelopes
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

TACE, transcatheter arterial chemoembolization; PEI, percutaneous ethanol injection; PMCT, percutaneous microwave coagulation therapy; KPS, Karnofsky performance status.

###### 

Solid tumor responses comparisons of HCC patients.

  Comparisons                 Studies                                                                              Groups      Clinical responses (%)   Heterogeneity   RR   95% CI   *P* value                       
  --------------------------- ------------------------------------------------------------------------------------ ----------- ------------------------ --------------- ---- -------- ----------- ------ ------------ ----------
  Complete response (CR)      \[[@B22], [@B23], [@B29], [@B30], [@B32], [@B34]--[@B36]\]                           Treatment   44/442 (10.0)            3.07            7    0.88     0           1.47   0.96--2.24   0.07
  Control                     26/406 (6.4)                                                                                                                                                                            
  Partial response (PR)       \[[@B20], [@B22]--[@B25], [@B27], [@B29], [@B30], [@B32], [@B34]--[@B36], [@B38]\]   Treatment   210/610 (34.4)           9.96            12   0.62     0           1.30   1.10--1.53   0.002
  Control                     145/551 (26.3)                                                                                                                                                                          
  Stable disease (SD)         \[[@B20], [@B22]--[@B25], [@B27], [@B29], [@B30], [@B32], [@B34]--[@B36], [@B38]\]   Treatment   260/610 (42.6)           15.89           12   0.2      24          0.95   0.84--1.08   0.47
  Control                     241/551 (43.7)                                                                                                                                                                          
  Progressive disease (PD)    \[[@B20], [@B22]--[@B25], [@B27], [@B29], [@B30], [@B32], [@B34]--[@B36], [@B38]\]   Treatment   101/610 (16.6)           9.22            12   0.68     0           0.64   0.52--0.80   \<0.0001
  Control                     146/551 (26.5)                                                                                                                                                                          
  Total response rate (tRR)   \[[@B20], [@B22]--[@B25], [@B27], [@B29], [@B30], [@B32], [@B34]--[@B36], [@B38]\]   Treatment   254/610 (41.6)           13.56           12   0.33     12          1.3    1.16--1.53   \<0.0001
  Control                     171/551 (31.0)                                                                                                                                                                          
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